gamma-aminobutyric acid and Chemical Dependence studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

Excerpt	Relevance	Reference
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."	8.80	Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia."	7.75	Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."	6.40	Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Alprazolam is an anxiolytic compound that can lead to psychological and physiological dependence especially with prolonged use."	5.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" This study utilized physiologically based pharmacokinetic (PK) and pharmacodynamic (PD) modelling to further examine the underlying mechanisms of anxiety treatment and addiction."	5.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" With repetitive administrations, peak concentration is 59 nM for a 2-mg alprazolam immediate-release dose and 122 nM for a 10-mg extended-release dose."	5.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability."	5.51	N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019)
"Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action."	5.35	Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment."	5.30	A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose."	5.30	A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"gov, and US FDA data, indexed through 28 July 2016, utilizing the following searches: pregabalin OR gabapentin OR gabapentinoid AND one of the following: abuse, misuse, overdose, or substance-related disorders[MESH], was conducted."	4.95	Abuse and Misuse of Pregabalin and Gabapentin. ( Evoy, KE; Morrison, MD; Saklad, SR, 2017)
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."	4.80	Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Pregabalin, primarily used to manage neuropathic pain and fibromyalgia, is categorized as a Schedule V drug (ie, lowest potential for abuse) in the US Drug Enforcement Administration's Controlled Substances Act."	3.76	Potential for pregabalin abuse or diversion after past drug-seeking behavior. ( Coren, JS; Filipetto, FA; Zipp, CP, 2010)
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia."	3.75	Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
" One promising pharmacological agent in BDZ discontinuation might be the newer anti-epileptic pregabalin, already successfully tested in the treatment of anxiety disorders."	3.74	Pregabalin in the discontinuation of long-term benzodiazepines' use. ( Karakatsanis, NA; Karapoulios, E; Konstantakopoulos, G; Kontoangelos, KA; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN, 2008)
"Histamine is a biogenic amine with four types of receptors."	2.82	Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. ( Di Ciano, P; Hendershot, CS; Le Foll, B, 2022)
"Substance use disorders are a leading cause of morbidity and mortality, and available pharmacological treatments are of modest efficacy."	2.82	Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. ( Di Ciano, P; Hendershot, CS; Le Foll, B, 2022)
" The starting dosage of pregabalin was 75 mg/day and was increased up to as much as 300 mg/day, depending on the individual patient's condition, while tapering off hypnotics."	2.79	Effects of pregabalin in patients with hypnotic-dependent insomnia. ( Cho, YW; Song, ML, 2014)
" Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone."	2.77	Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. ( Coalson, DW; Paice, JA; Zacny, JP, 2012)
"Gabapentin (1200 mg/day) was additionally added in group B."	2.71	Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003)
"Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase."	2.71	Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003)
"Risk factors include a history of substance abuse, particularly opioids, and psychiatric co-morbidities."	2.55	Abuse and Misuse of Pregabalin and Gabapentin. ( Evoy, KE; Morrison, MD; Saklad, SR, 2017)
"Gabapentin was misused primarily for recreational purposes, self-medication or intentional self-harm and was misused alone or in combination with other substances, especially opioids, benzodiazepines and/or alcohol."	2.53	Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Databases were searched for peer-reviewed papers demonstrating gabapentin misuse, characterized by taking a larger dosage than prescribed or taking gabapentin without a prescription, and diversion."	2.53	Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Individuals with histories of drug abuse were most often involved in its misuse."	2.53	Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Drug addiction is characterized by widespread abnormalities in brain function and neurochemistry, including drug-associated effects on concentrations of the excitatory and inhibitory neurotransmitters glutamate and gamma-aminobutyric acid (GABA), respectively."	2.53	Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity. ( London, ED; Moeller, SJ; Northoff, G, 2016)
"A history of alcohol or substance abuse appears to be an important part of a patient's medical history when evaluating their risk for addiction and dependence behaviors."	2.53	Gabapentin: Abuse, Dependence, and Withdrawal. ( Mersfelder, TL; Nichols, WH, 2016)
" Overall, pregabalin is characterized by higher potency, quicker absorption rates and greater bioavailability levels than gabapentin."	2.50	Misuse and abuse of pregabalin and gabapentin: cause for concern? ( Schifano, F, 2014)
"Problematic compounds may cause seizures either acutely or on withdrawal: Their use may reduce effectiveness of antiepileptic drugs, or may simply promote and enhance chaotic lifestyles."	2.48	Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. ( Borland, W; Leach, JP; Mohanraj, R, 2012)
" In both conditions, PGB was found efficacious with significant improvement in withdrawal symptoms at the dosage ranges of 150-450 mg/day (AD) and 225-900 mg/day (BD)."	2.46	Pregabalin in the treatment of alcohol and benzodiazepines dependence. ( Konstantakopoulos, G; Oulis, P, 2010)
"Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work."	2.44	Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007)
"Drug addiction is a process beginning with the initial exposure to a drug of abuse, and leading, in some individuals, to chronic habitual use, and high rates of relapse."	2.44	Microdialysis and the neurochemistry of addiction. ( Kalivas, PW; Torregrossa, MM, 2008)
"The successful intervention into alcohol dependence and craving brought about by baclofen in both human and animal studies elucidates glutamatergic mechanisms in alcoholism whereas the role of the dopamine transporter, in conjunction with both the noradrenergic and serotonergic transporters, are implicated in cocaine dependence and craving."	2.42	Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. ( Archer, T; Beninger, RJ; Kostrzewa, RM; Palomo, T, 2004)
"Conventional wisdom, and even well-reasoned theoretical mechanisms, suggests that the chronic use of psychoactive substances would impair cognitive functioning of individuals."	2.42	Cognitive impairment in substance abuse. ( Cellucci, T; Hedt, J; Jarchow, A; Vik, PW, 2004)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."	2.40	Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U."	2.37	[Phencyclidine, a drug which induces psychosis: its neuropharmacological actions]. ( Furukawa, H; Kameyama, T; Nabeshima, T, 1984)
" This study utilized physiologically based pharmacokinetic (PK) and pharmacodynamic (PD) modelling to further examine the underlying mechanisms of anxiety treatment and addiction."	1.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" With repetitive administrations, peak concentration is 59 nM for a 2-mg alprazolam immediate-release dose and 122 nM for a 10-mg extended-release dose."	1.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Alprazolam is an anxiolytic compound that can lead to psychological and physiological dependence especially with prolonged use."	1.91	Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines."	1.62	Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
" Chronic use of these GABAergic drugs can lead to significant withdrawal syndromes."	1.62	Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
"Flunitrazepam is a newer benzodiazepine that is preferentially used recreationally and to facilitate sexual assault."	1.62	Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
"Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability."	1.51	N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019)
"Gabapentin misuse has been associated with drug-related harm and increased healthcare service utilization in a few studies, including a recent large-sample analysis of commercially insured enrollees in the United States (U."	1.48	Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? ( Fairman, KA; Peckham, AM; Sclar, DA, 2018)
" Whereas chronic administration of the cannabinoid receptor agonist WIN55,212 (WIN) resulted in increased basal GABA release, the D2 agonist receptor-mediated control of GABA and DA release elicited by quinpirole was similar in both cannabinoid-dependent and non dependent animals."	1.48	Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. ( Decara, J; Edwards, S; Moreno, M; Parsons, LH; Pavon, FJ; Rodríguez de Fonseca, F; Serrano, A; Stouffer, DG; Suárez, J, 2018)
"Smoking polysubstance users were more impulsive than smokers, and both groups were more impulsive than controls."	1.46	Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. ( Goudriaan, AE; Homberg, JR; Kaag, AM; Reneman, L; Schmaal, L; Schulte, MHJ; van den Brink, W; van Wingen, GA; Wiers, RW, 2017)
"Fifty-eight percent had an opioid use disorder, again mostly in combination with other drugs and/or alcohol."	1.43	Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016)
" Its desired and adverse effects appear similar to other gamma-aminobutyric acid receptor agonists."	1.43	Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
" According to the grey literature, phenibut is taken for its anxiolytic and euphoric properties, with tolerance and withdrawal syndromes commonly reported adverse effects."	1.43	Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
" To gather information on prevalence of use, desired effects and/or adverse effects, we searched grey literature (online drug discussion forums) and medical literature (PubMed and abstracts from selected International Toxicology conferences)."	1.43	Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
"All patients had substance use disorders, the large majority (72 %) to more than one substance."	1.43	Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016)
"Carisoprodol is a widely prescribed muscle relaxant, abuse of which has grown considerably in recent years."	1.42	Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors. ( Dillon, GH; González, LA; Kumar, M, 2015)
"In the drug abuser cases, PRG poisoning represented 19."	1.40	Profiles of pregabalin and gabapentin abuse by postmortem toxicology. ( Gergov, M; Häkkinen, M; Kalso, E; Ojanperä, I; Vuori, E, 2014)
"Drug abuse was associated with 48."	1.40	Profiles of pregabalin and gabapentin abuse by postmortem toxicology. ( Gergov, M; Häkkinen, M; Kalso, E; Ojanperä, I; Vuori, E, 2014)
" Mean daily PRG dosage was 1424 mg."	1.39	Pregabalin abuse and dependence in Germany: results from a database query. ( Freudenmann, RW; Gahr, M; Hiemke, C; Kölle, MA; Schönfeldt-Lecuona, C, 2013)
"Some patients had no known history of substance abuse."	1.38	Gabapentin and pregabalin: abuse and addiction. ( , 2012)
"Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action."	1.35	Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Tolerance, dependence, and adverse effects on cognitive functions are well-known consequences of long-term use of benzodiazepines (BDZ), especially at high doses, raising thorny therapeutic problems in their discontinuation."	1.35	Pregabalin in the discontinuation of long-term benzodiazepines' use. ( Karakatsanis, NA; Karapoulios, E; Konstantakopoulos, G; Kontoangelos, KA; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN, 2008)
"Zolpidem is an imidazopyridine hypnotic that is believed to act selectively at alpha(1) subunit-containing gamma-aminobutyric acid type A (GABA(A)) receptors and thus to have minimal abuse and dependence potential."	1.32	Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. ( Christodoulou, GN; Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Malitas, PN; Nikolaou, CK, 2003)
"Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment."	1.30	A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose."	1.30	A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
" In the test of physical dependence-producing potential with the drug-admixed food method in rats, vigabatrin and diazepam were given to rats mixed with food for 28 days in an increasing dosage schedule, followed by feeding a drug-free diet to observe withdrawal signs for 7 days."	1.30	Drug dependence study on vigabatrin in rhesus monkeys and rats. ( Takada, K; Yanagita, T, 1997)
"Vigabatrin proved to be a potent anticonvulsant drug at acute doses (100-200 mg/kg), but during chronic administration, the anticonvulsant activity of the treatment was lost already in the second week of treatment."	1.28	Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats. ( Löscher, W; Rundfeldt, C, 1992)
"Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines."	1.27	Neuropharmacology of buspirone. ( Eison, AS; Eison, MS; Riblet, LA; Taylor, DP; Temple, DL; VanderMaelen, CP, 1984)
" Prevention is easy if treatment is gradually rather than abruptly withdrawn in all patients who receive the compound in high dosage for more than one month."	1.26	[Benzodiazepine physical dependence. 6 cases (author's transl)]. ( Bismuth, C; Dally, S; Lagier, G; Le Bellec, M, 1980)
"Rats exposed to chronic intake of sodium barbital maintained high circulating levels of barbital in blood and brain and exhibited increased sensitivity ot audiogenic convulsions during the withdrawal period."	1.26	Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal. ( Hawkins, TD; Kant, GJ; Lenox, RH; Meyerhoff, JL; Wray, HL, 1979)

Research

Studies (167)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back

Timeframe	Studies, this research(%)	All Research%
pre-1990	25 (14.97)	18.7374
1990's	19 (11.38)	18.2507
2000's	36 (21.56)	29.6817
2010's	74 (44.31)	24.3611
2020's	13 (7.78)	2.80

Authors	Studies
Tran, MN	1
Maynard, KR	1
Spangler, A	1
Huuki, LA	1
Montgomery, KD	1
Sadashivaiah, V	1
Tippani, M	1
Barry, BK	1
Hancock, DB	1
Hicks, SC	1
Kleinman, JE	1
Hyde, TM	1
Collado-Torres, L	1
Jaffe, AE	1
Martinowich, K	1
Subramaniam, P	1
Prescot, A	1
McGlade, E	1
Renshaw, P	1
Yurgelun-Todd, D	1
Di Ciano, P	1
Hendershot, CS	1
Le Foll, B	1
Wainblat, E	1
Weleff, J	1
Anand, A	1
Burkat, PM	1
Nudmamud-Thanoi, S	1
Veerasakul, S	1
Thanoi, S	1
Kokane, SS	1
Armant, RJ	1
Bolaños-Guzmán, CA	1
Perrotti, LI	1
Kupats, E	1
Vrublevska, J	1
Zvejniece, B	1
Vavers, E	1
Stelfa, G	1
Zvejniece, L	1
Dambrova, M	1
Barker, JS	1
Hines, RM	1
López-Gambero, AJ	1
Rodríguez de Fonseca, F	2
Suárez, J	2
Mash, JE	1
Leo, RJ	1
Li, X	1
Slesinger, PA	1
Doyno, CR	1
White, CM	1
Peckham, AM	2
Fairman, KA	2
Sclar, DA	2
Buttram, ME	1
Kurtz, SP	1
Dart, RC	1
Margolin, ZR	1
Joshi, YB	1
Friend, SF	1
Jimenez, B	1
Steiger, LR	1
Schulte, MHJ	1
Kaag, AM	1
Wiers, RW	1
Schmaal, L	1
van den Brink, W	1
Reneman, L	1
Homberg, JR	1
van Wingen, GA	1
Goudriaan, AE	1
Heeren, N	1
Farver, D	1
Bonnet, U	2
Scherbaum, N	3
Puhl, MD	1
Desai, RI	1
Takagi, S	1
Presti, KT	1
Doyle, MR	1
Donahue, RJ	1
Landino, SM	1
Bergman, J	1
Carlezon, WA	1
Coyle, JT	1
Throckmorton, DC	1
Gottlieb, S	1
Woodcock, J	1
Richter, EL	1
Isbruch, K	1
Tomko, JR	1
Prasad, KM	1
Kubas, S	1
Simpson, T	1
Moreno, M	1
Decara, J	1
Pavon, FJ	1
Stouffer, DG	2
Edwards, S	1
Serrano, A	1
Parsons, LH	2
Hardman, MI	1
Sprung, J	1
Weingarten, TN	1
Jouney, EA	1
Konen, C	1
Niederst, E	1
Westin, AA	3
Bramness, JG	2
Chalabianloo, F	2
Rygnestad, T	1
Slørdal, L	2
Cruz, MT	1
Bajo, M	1
Schweitzer, P	1
Roberto, M	2
Kumar, K	1
Sharma, S	1
Kumar, P	2
Deshmukh, R	1
Grosshans, M	2
Lemenager, T	1
Vollmert, C	1
Kaemmerer, N	1
Schreiner, R	1
Mutschler, J	2
Wagner, X	1
Kiefer, F	2
Hermann, D	2
Rohman, L	1
Hebron, A	1
Bodén, R	1
Wettermark, B	1
Brandt, L	1
Kieler, H	1
Baird, CR	1
Fox, P	1
Colvin, LA	1
Oulis, P	3
Kalogerakou, S	1
Anyfandi, E	1
Konstantakopoulos, G	3
Papakosta, VM	1
Masdrakis, V	1
Tsaltas, E	1
Howland, RH	2
O'Connell, CW	1
Schneir, AB	1
Hwang, JQ	1
Cantrell, FL	1
Schifano, F	3
Cho, YW	1
Song, ML	1
Häkkinen, M	1
Vuori, E	1
Kalso, E	1
Gergov, M	1
Ojanperä, I	1
Papazisis, G	1
Tzachanis, D	1
Aligny, C	1
Roux, C	1
Dourmap, N	1
Ramdani, Y	1
Do-Rego, JC	1
Jégou, S	1
Leroux, P	1
Leroux-Nicollet, I	1
Marret, S	1
Gonzalez, BJ	1
Davydova, TV	1
Vetrile, LA	1
Nevidimova, TI	1
Vetlugina, TP	1
Fomina, VG	1
Zakharova, IA	1
Batukhtina, EI	1
Bokhan, NA	1
Jonsson, B	1
Backman, E	1
Salmonson, H	1
Höjer, J	1
Kumar, M	1
González, LA	1
Dillon, GH	1
Smith, RV	2
Lofwall, MR	1
Havens, JR	2
Moeller, SJ	1
London, ED	1
Northoff, G	1
Owen, DR	1
Wood, DM	1
Archer, JR	1
Dargan, PI	1
Mersfelder, TL	1
Nichols, WH	1
Barker, DJ	1
Root, DH	1
Zhang, S	1
Morales, M	1
Izumi, Y	1
Zorumski, CF	1
Bastiaens, L	1
Galus, J	1
Mazur, C	1
Mariani, JJ	1
Malcolm, RJ	2
Mamczur, AK	1
Choi, JC	1
Brady, R	1
Nunes, E	1
Levin, FR	1
Walsh, SL	1
Chiappini, S	1
Evoy, KE	1
Morrison, MD	1
Saklad, SR	1
Ferré, S	1
Quiroz, C	1
Woods, AS	1
Cunha, R	1
Popoli, P	1
Ciruela, F	1
Lluis, C	1
Franco, R	1
Azdad, K	1
Schiffmann, SN	1
Forde, G	1
Stanos, S	1
Apgar, BS	1
Uhart, M	1
Wand, GS	1
Heberlein, A	1
Bleich, S	1
Kornhuber, J	1
Hillemacher, T	1
Schjøtt, J	1
Mondón, S	1
Nogué, S	1
Urbano, D	1
Rovira, E	1
Xi, ZX	1
Gardner, EL	1
Kruszewski, SP	1
Paczynski, RP	1
Kahn, DA	1
Conner, BT	1
Hellemann, GS	1
Ritchie, TL	1
Noble, EP	1
Raza, S	1
Siddiqui, UA	1
Megna, JL	1
Schwartz, TL	1
Batki, SL	1
Rawls, SM	1
Patil, T	1
Yuvasheva, E	1
Raffa, RB	1
Schwan, S	1
Sundström, A	1
Stjernberg, E	1
Hallberg, E	1
Hallberg, P	1
Klein, O	1
Dressing, H	1
Mann, K	1
Caster, O	1
Edwards, IR	1
Norén, GN	1
Lindquist, M	1
Strøm, EJ	2
Filipetto, FA	1
Zipp, CP	1
Coren, JS	1
Kurokawa, K	1
Shibasaki, M	1
Mizuno, K	1
Ohkuma, S	1
D'Offizi, S	1
Piccione, M	1
Corazza, O	1
Deluca, P	1
Davey, Z	1
Di Melchiorre, G	1
Di Furia, L	1
Farré, M	1
Flesland, L	1
Mannonen, M	1
Majava, A	1
Pagani, S	1
Peltoniemi, T	1
Siemann, H	1
Skutle, A	1
Torrens, M	1
Pezzolesi, C	1
van der Kreeft, P	1
Landmark, CJ	2
Fossmark, H	1
Larsson, PG	2
Rytter, E	2
Johannessen, SI	2
Helland, A	2
Rubio, G	1
Bobes, J	1
Cervera, G	1
Terán, A	1
Pérez, M	1
López-Gómez, V	1
Rejas, J	1
Changeux, JP	1
Lou, HC	1
Barrot, M	1
Thome, J	1
Addolorato, G	1
Leggio, L	1
Hopf, FW	1
Diana, M	1
Bonci, A	1
Zacny, JP	1
Paice, JA	1
Coalson, DW	1
Conesa, ML	1
Rojo, LM	1
Plumed, J	1
Livianos, L	1
Schroll, J	1
Martinotti, G	1
Shameem, M	1
Patel, AB	1
Leach, JP	1
Mohanraj, R	1
Borland, W	1
Gahr, M	1
Freudenmann, RW	1
Hiemke, C	1
Kölle, MA	1
Schönfeldt-Lecuona, C	1
Persheim, MS	1
Spigset, O	1
Samokhvalov, AV	1
Paton-Gay, CL	1
Balchand, K	1
Rehm, J	1
Liappas, IA	1
Malitas, PN	1
Dimopoulos, NP	1
Gitsa, OE	1
Liappas, AI	1
Nikolaou, CK	1
Christodoulou, GN	1
Voris, J	1
Smith, NL	1
Rao, SM	1
Thorne, DL	1
Flowers, QJ	1
Hu, JH	1
Yang, N	1
Ma, YH	1
Zhou, XG	1
Jiang, J	1
Duan, SH	1
Mei, ZT	1
Fei, J	1
Guo, LH	1
Jain, MK	1
Vik, PW	1
Cellucci, T	1
Jarchow, A	1
Hedt, J	1
Ikemoto, S	1
Wise, RA	1
Petit, TL	1
Madamba, SG	1
Siggins, GR	1
Palomo, T	1
Kostrzewa, RM	1
Beninger, RJ	1
Archer, T	1
Berghuis, P	1
Dobszay, MB	1
Wang, X	1
Spano, S	1
Ledda, F	1
Sousa, KM	1
Schulte, G	1
Ernfors, P	1
Mackie, K	1
Paratcha, G	1
Hurd, YL	1
Harkany, T	1
Crunelli, V	1
Emri, Z	1
Leresche, N	1
Laviolette, SR	1
Grace, AA	1
Heinzerling, KG	1
Shoptaw, S	1
Peck, JA	1
Yang, X	1
Liu, J	1
Roll, J	1
Ling, W	1
Amin, Z	1
Mason, GF	1
Cavus, I	1
Krystal, JH	1
Rothman, DL	1
Epperson, CN	1
Victorri-Vigneau, C	1
Guerlais, M	1
Jolliet, P	1
Nugent, FS	1
Penick, EC	1
Kauer, JA	1
Brewer, JA	1
Potenza, MN	1
Howell, LL	1
Kimmel, HL	1
Urschel, HC	1
Hanselka, LL	1
Gromov, I	1
White, L	1
Baron, M	1
Torregrossa, MM	1
Kalivas, PW	1
Klempan, TA	1
Sequeira, A	1
Canetti, L	1
Lalovic, A	1
Ernst, C	1
ffrench-Mullen, J	1
Turecki, G	1
Kouzoupis, AV	1
Masdrakis, VG	1
Karakatsanis, NA	1
Karapoulios, E	1
Kontoangelos, KA	1
Papadimitriou, GN	1
DeFeudis, FV	1
Bismuth, C	1
Le Bellec, M	1
Dally, S	1
Lagier, G	1
Carranza, J	1
Danneberg, P	1
Weber, KH	1
Haefely, W	1
Riblet, LA	1
Eison, AS	1
Eison, MS	1
Taylor, DP	1
Temple, DL	1
VanderMaelen, CP	1
Nabeshima, T	1
Furukawa, H	1
Kameyama, T	1
Lorini, G	1
Fazio, L	1
Fusari, A	1
Cocchi, R	3
Schoffelmeer, AN	1
De Vries, TJ	1
Vanderschuren, LJ	1
Tjon, GH	1
Nestby, P	1
Wardeh, G	1
Mulder, AH	1
Nabeshima, A	2
Saito, T	3
Takahata, N	3
Toki, S	2
Fricchione, GL	1
Mendoza, A	1
Stefano, GB	1
White, FJ	1
Hatta, S	1
Maitre, M	1
Javitt, DC	1
Frusciante, M	1
Bhaumik, S	1
Branford, D	1
Duggirala, C	1
Ismail, IA	1
Markowitz, JS	2
Finkenbine, R	1
Myrick, H	1
King, L	1
Carson, WH	1
Koob, GF	2
Takada, K	1
Yanagita, T	1
Bernasconi, R	1
Mathivet, P	1
Bischoff, S	1
Marescaux, C	1
Letterman, L	1
Scearce-Levie, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027]	Phase 2	5 participants (Actual)	Interventional	2022-04-01	Terminated (stopped due to Low enrollment rate)
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192]	Phase 2	50 participants (Anticipated)	Interventional	2022-01-10	Enrolling by invitation
A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients[NCT00420771]	Phase 2	19 participants (Actual)	Interventional	2007-01-31	Completed
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]	Phase 4	77 participants (Actual)	Interventional	2018-05-15	Completed
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908]	Phase 3	252 participants (Anticipated)	Interventional	2016-09-30	Active, not recruiting
A Post Marketing Study to Evaluate the Safety and Efficacy of Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use[NCT04659278]		0 participants (Actual)	Interventional	2021-09-30	Withdrawn (stopped due to Study has been placed on hold)
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults[NCT01320748]		29 participants (Actual)	Interventional	2011-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Comparing the mean reduction change in Benzodiazepine use per day when comparing the baseline week prior to study entry to the last week of study participation based on the Time Line Follow Back (NCT00420771)
Timeframe: data collected during 8 weeks of trial or length of participation

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Intervention	milligrams/day (Mean)
Active Medication	4.0
Placebo	2.3

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Intervention	score on 10-point scale (Mean)
Standard of Care	2.26
Postoperative Gabapentin Regimen	2.46

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 3: How Well Are You Sleeping?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	3.84
Postoperative Gabapentin Regimen	3.54

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 4: How Bad is Your Nausea?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	5.73
Postoperative Gabapentin Regimen	6.38

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	0.36
Postoperative Gabapentin Regimen	0.17

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Days Taking Opioids

Intervention	score on a 10-point scale (Mean)
Standard of Care	7.83
Postoperative Gabapentin Regimen	8.48

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Opioid Consumption

Intervention	days (Mean)
Standard of Care	14.8
Postoperative Gabapentin Regimen	18.7

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Article	Year
Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. Current topics in behavioral neurosciences, 2022, Volume: 59 Topics: Acetylcholine; Animals; Autoreceptors; Central Nervous System Stimulants; Dopamine; Ethanol; gamma-A	2022
Pharmacogenetics of drug dependence: Polymorphisms of genes involved in GABA neurotransmission. Neuroscience letters, 2020, 05-01, Volume: 726 Topics: Animals; gamma-Aminobutyric Acid; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Recepto	2020
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behavioural brain research, 2020, 04-20, Volume: 384 Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder,	2020
Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports. Pharmacopsychiatry, 2020, Volume: 53, Issue:5 Topics: Anti-Anxiety Agents; gamma-Aminobutyric Acid; Humans; Nootropic Agents; Substance-Related Disorders	2020
Regulation of GABA International journal of molecular sciences, 2020, Jun-22, Volume: 21, Issue:12 Topics: Animals; gamma-Aminobutyric Acid; Gene Expression Regulation; Humans; Protein Subunits; Receptors, G	2020
Energy sensors in drug addiction: A potential therapeutic target. Addiction biology, 2021, Volume: 26, Issue:2 Topics: AMP-Activated Protein Kinases; Brain; Dopamine; Dopaminergic Neurons; G Protein-Coupled Inwardly-Rec	2021
How addictive are gabapentin and pregabalin? A systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:12 Topics: Amines; Analgesics; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Bibliographic; Drug	2017
On the addictive power of gabapentinoids: a mini-review. Psychiatria Danubina, 2018, Volume: 30, Issue:2 Topics: Adult; Amines; Animals; Comorbidity; Craving; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu	2018
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian journal of basic medical sciences, 2019, May-20, Volume: 19, Issue:2 Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor	2019
Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction. Current psychiatry reports, 2019, 03-09, Volume: 21, Issue:4 Topics: Behavior, Addictive; Dietary Supplements; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives;	2019
Shared mechanisms of alcohol and other drugs. Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2008, Volume: 31, Issue:2 Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Animals; Cannabinoids; gamma-Aminobutyric Acid; Hu	2008
Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacology, biochemistry, and behavior, 2013, Volume: 110 Topics: Anxiety; Central Nervous System Diseases; Depression; GABA Modulators; gamma-Aminobutyric Acid; Huma	2013
Gabapentin for the treatment of substance use disorders. Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:12 Topics: Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans;	2013
Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS drugs, 2014, Volume: 28, Issue:6 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Prescr	2014
Pregabalin's abuse potential: a mini review focusing on the pharmacological profile. International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:8 Topics: Analgesics; Animals; Behavior, Addictive; gamma-Aminobutyric Acid; Humans; Neurons; Practice Pattern	2014
Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity. Neuroscience and biobehavioral reviews, 2016, Volume: 61 Topics: Animals; Brain; Brain Mapping; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neuroimaging; Substan	2016
Gabapentin: Abuse, Dependence, and Withdrawal. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr	2016
Gabapentin: Abuse, Dependence, and Withdrawal. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr	2016
Gabapentin: Abuse, Dependence, and Withdrawal. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr	2016
Gabapentin: Abuse, Dependence, and Withdrawal. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr	2016
Multiplexed neurochemical signaling by neurons of the ventral tegmental area. Journal of chemical neuroanatomy, 2016, Volume: 73 Topics: Animals; Behavior; Depression; Dopamine; gamma-Aminobutyric Acid; Habenula; Humans; Neurons; Neurotr	2016
Gabapentin misuse, abuse and diversion: a systematic review. Addiction (Abingdon, England), 2016, Volume: 111, Issue:7 Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Prescr	2016
Abuse and Misuse of Pregabalin and Gabapentin. Drugs, 2017, Volume: 77, Issue:4 Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Overdose; Gabapentin; gamma-Aminobutyric Acid;	2017
An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Current pharmaceutical design, 2008, Volume: 14, Issue:15 Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenylyl Cyclases; Animals; Basal	2008
Practical management strategies for the chronic pain patient. The Journal of family practice, 2007, Volume: 56, Issue:8 Suppl Ho Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro	2007
Stress, alcohol and drug interaction: an update of human research. Addiction biology, 2009, Volume: 14, Issue:1 Topics: Alcoholism; Allostasis; Animals; Arousal; Brain; Corticotropin-Releasing Hormone; Cues; Dopamine; ga	2009
[Benzodiazepine dependence: causalities and treatment options]. Fortschritte der Neurologie-Psychiatrie, 2009, Volume: 77, Issue:1 Topics: Animals; Benzodiazepines; Corticotropin-Releasing Hormone; gamma-Aminobutyric Acid; Humans; Hypnotic	2009
[Pregabalin and its potential for abuse]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2009, Jan-29, Volume: 129, Issue:3 Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pregabalin; Risk Factors; Substance-Related Disorders	2009
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Current drug abuse reviews, 2008, Volume: 1, Issue:3 Topics: Animals; Brain; Cannabinoid Receptor Modulators; Central Nervous System Stimulants; Cocaine-Related	2008
Pregabalin in the treatment of alcohol and benzodiazepines dependence. CNS neuroscience & therapeutics, 2010,Spring, Volume: 16, Issue:1 Topics: Alcoholism; Anticonvulsants; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance	2010
Emergent pharmacology of conscious experience: new perspectives in substance addiction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:7 Topics: Animals; Brain; Consciousness; GABA Modulators; gamma-Aminobutyric Acid; Humans; Models, Neurologica	2011
Discovering a new anatomical structure in the brain: implications for neuropsychiatry and therapy. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2011, Volume: 12 Suppl 1 Topics: Animals; Arousal; Brain; Brain Mapping; Diffusion Magnetic Resonance Imaging; Dopamine; Drug Deliver	2011
Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:1 Topics: Alcoholism; Brain Chemistry; gamma-Aminobutyric Acid; Humans; Ion Channels; Substance-Related Disord	2012
Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. Epilepsia, 2012, Volume: 53 Suppl 4 Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Alcoholism; Amphetamine-Related Disorders; Benzodiaze	2012
Cognitive impairment in substance abuse. The Psychiatric clinics of North America, 2004, Volume: 27, Issue:1 Topics: Alcohol Amnestic Disorder; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Eth	2004
Mapping of chemical trigger zones for reward. Neuropharmacology, 2004, Volume: 47 Suppl 1 Topics: Acetylcholine; Animals; Behavior, Animal; Brain; Brain Mapping; Carbachol; Dopamine; Drug Delivery S	2004
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. Neurotoxicity research, 2004, Volume: 6, Issue:5 Topics: Alcoholism; Biogenic Monoamines; Event-Related Potentials, P300; gamma-Aminobutyric Acid; Humans; Pe	2004
Unravelling the brain targets of gamma-hydroxybutyric acid. Current opinion in pharmacology, 2006, Volume: 6, Issue:1 Topics: Animals; Brain; Epilepsy, Absence; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Humans; Hydrox	2006
The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cellular and molecular life sciences : CMLS, 2006, Volume: 63, Issue:14 Topics: Amygdala; Animals; Appetitive Behavior; Arachidonic Acids; Association Learning; Cannabinoids; Centr	2006
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. Pharmacology, biochemistry, and behavior, 2006, Volume: 84, Issue:4 Topics: Affect; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; Menstruation; Mental Disord	2006
The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1 Topics: Animals; Decision Making; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Endorphins;	2008
Monoamine transporters and psychostimulant addiction. Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1 Topics: Animals; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Plasma Membrane Transpor	2008
Microdialysis and the neurochemistry of addiction. Pharmacology, biochemistry, and behavior, 2008, Volume: 90, Issue:2 Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Microdialysis; Neuronal Plasticity; Serot	2008
Chemical structure and biological activity of the diazepines. British journal of clinical pharmacology, 1983, Volume: 16 Suppl 2 Topics: Acetylcholine; Aggression; Animals; Anti-Anxiety Agents; Anxiety; Autonomic Nervous System; Behavior	1983
[Phencyclidine, a drug which induces psychosis: its neuropharmacological actions]. Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology, 1984, Volume: 4, Issue:2 Topics: Acetylcholine; Animals; Behavior, Animal; Binding Sites; Brain; Cats; Dogs; Dopamine; Drug Tolerance	1984
Morphine and its psychiatric implications. Advances in neuroimmunology, 1994, Volume: 4, Issue:2 Topics: Animals; Anxiety, Separation; Cathexis; Dopamine; gamma-Aminobutyric Acid; Gene Expression Regulatio	1994
Synaptic regulation of mesocorticolimbic dopamine neurons. Annual review of neuroscience, 1996, Volume: 19 Topics: Afferent Pathways; Animals; Antipsychotic Agents; Dopamine; Excitatory Amino Acids; gamma-Aminobutyr	1996
The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Progress in neurobiology, 1997, Volume: 51, Issue:3 Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Mammals; Models, Neurological; Rats; Receptors, GAB	1997
Drug abuse and alcoholism. Overview. Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42 Topics: Alcoholism; Animals; Brain; Cocaine; Dopamine; Emotions; gamma-Aminobutyric Acid; Humans; Membrane G	1998
Circuits, drugs, and drug addiction. Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42 Topics: Amygdala; Animals; Benzazepines; Brain; Cocaine; Dextroamphetamine; Dopamine; gamma-Aminobutyric Aci	1998
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy, 1999, Volume: 19, Issue:5 Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti	1999
Nociceptin/orphanin FQ and drugs of abuse. Peptides, 2000, Volume: 21, Issue:7 Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Behavior; Brain; Dopamine; gamma-Aminobutyric Acid; G	2000
GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug and alcohol dependence, 2002, Feb-01, Volume: 65, Issue:3 Topics: Animals; Baclofen; Brain; Dopamine; GABA Agonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid	2002
Isolation and characterization of membrane drug receptors. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 1976, Volume: 20 Topics: Animals; Drug Tolerance; gamma-Aminobutyric Acid; Glucagon; Glycine; Humans; Insulin; Insulin Resist	1976
gamma-aminobutyric acid in alcohol, barbiturate and morphine dependence: a review. The British journal of addiction to alcohol and other drugs, 1977, Volume: 72, Issue:2 Topics: Alcoholism; Aminobutyrates; Animals; Barbiturates; Brain; Ethanol; gamma-Aminobutyric Acid; Humans;	1977
Roles of serotonin and gamma-aminobutyric acid in opioid effects. Advances in biochemical psychopharmacology, 1979, Volume: 20 Topics: Analgesia; Analgesics; Body Temperature Regulation; Drug Tolerance; Electric Stimulation; gamma-Amin	1979
Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Neuropeptides, 1991, Volume: 19 Suppl Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Cholecystokinin; gamma-Aminobutyric Acid; Indoles; Meg	1991
Barbiturates and the GABAA receptor complex. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 1990, Volume: 34 Topics: Animals; Barbiturates; Drug Tolerance; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; Substance	1990
The GABA system in functional tolerance and dependence following barbiturates, benzodiazepines or ethanol--correlation or causality? Comparative biochemistry and physiology. A, Comparative physiology, 1989, Volume: 93, Issue:1 Topics: Alcoholism; Animals; Barbiturates; Benzodiazepines; Drug Tolerance; gamma-Aminobutyric Acid; Neurons	1989
Control vs. lack of control over aversive stimuli: nonopioid-opioid analgesic consequences. NIDA research monograph, 1986, Volume: 74 Topics: Analgesia; Animals; Electroshock; gamma-Aminobutyric Acid; Humans; Internal-External Control; Models	1986

Article	Year
Effects of pregabalin in patients with hypnotic-dependent insomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2014, May-15, Volume: 10, Issue:5 Topics: Female; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pregabalin; Sle	2014
Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. The American journal of drug and alcohol abuse, 2016, Volume: 42, Issue:3 Topics: Adolescent; Adult; Aged; Amines; Benzodiazepines; Combined Modality Therapy; Cyclohexanecarboxylic A	2016
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. European addiction research, 2011, Volume: 17, Issue:5 Topics: Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Female; gamma-Aminobutyric Acid; Humans; Male;	2011
Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3 Topics: Adult; Analgesics; Analgesics, Opioid; Anticonvulsants; Cross-Over Studies; Dose-Response Relationsh	2012
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. The Journal of the Association of Physicians of India, 2003, Volume: 51 Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy	2003
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug and alcohol dependence, 2006, Dec-01, Volume: 85, Issue:3 Topics: Adult; Amines; Anti-Anxiety Agents; Baclofen; Central Nervous System Stimulants; Cyclohexanecarboxyl	2006

Article	Year
Single-nucleus transcriptome analysis reveals cell-type-specific molecular signatures across reward circuitry in the human brain. Neuron, 2021, 10-06, Volume: 109, Issue:19 Topics: Brain; Brain Mapping; Cell Nucleus; gamma-Aminobutyric Acid; Gene Expression Profiling; Genome-Wide	2021
Examination of gamma-aminobutyric acid and glutamate-glutamine levels in association with impulsive behavior in adolescent marijuana users. Drug and alcohol dependence, 2022, 04-01, Volume: 233 Topics: Adolescent; Cannabis; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Impulsive Behavior;	2022
Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2023, Volume: 31, Issue:1 Topics: Aged; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Substance-Rel	2023
Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. British journal of clinical pharmacology, 2023, Volume: 89, Issue:8 Topics: Alprazolam; Anti-Anxiety Agents; Anxiety; gamma-Aminobutyric Acid; Humans; Substance-Related Disorde	2023
Phenibut: A Novel Nootropic With Abuse Potential. The primary care companion for CNS disorders, 2020, Aug-13, Volume: 22, Issue:4 Topics: Adult; gamma-Aminobutyric Acid; Humans; Male; Nootropic Agents; Substance Withdrawal Syndrome; Subst	2020
GABA Current topics in behavioral neurosciences, 2022, Volume: 52 Topics: gamma-Aminobutyric Acid; Humans; Pharmaceutical Preparations; Receptors, GABA-B; Substance-Related D	2022
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. Journal of clinical pharmacology, 2021, Volume: 61 Suppl 2 Topics: Drug Overdose; Flunitrazepam; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Oligopeptide	2021
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population. Clinical drug investigation, 2017, Volume: 37, Issue:8 Topics: Adolescent; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;	2017
Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiology and drug safety, 2017, Volume: 26, Issue:9 Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Data Collection; Female; Gabapentin; gamma-Aminobut	2017
Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:4 Topics: Adult; Baclofen; Delirium; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Substance Withdrawa	2017
Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. Drug and alcohol dependence, 2017, 10-01, Volume: 179 Topics: Cigarette Smoking; Cocaine-Related Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli;	2017
You Abused What? Getting High with Unique Medications. South Dakota medicine : the journal of the South Dakota State Medical Association, 2017, Volume: 70, Issue:1 Topics: Amines; Anticonvulsants; Antidiarrheals; Antipsychotic Agents; Antitussive Agents; Cyclohexanecarbox	2017
Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? Expert opinion on drug safety, 2018, Volume: 17, Issue:5 Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug and Narcotic Control; Gabapentin; gamma-Aminob	2018
N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. Addiction biology, 2019, Volume: 24, Issue:1 Topics: Animals; Cocaine; Comorbidity; Dopamine; Dopamine Uptake Inhibitors; gamma-Aminobutyric Acid; Glutam	2019
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance. The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3 Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization	2018
The Association of Gabapentin Use and Dose With Substance Use Disorders Prior to Inpatient Mental Health Treatment: A Cross-Sectional Study. The primary care companion for CNS disorders, 2018, Aug-02, Volume: 20, Issue:4 Topics: Adult; Amines; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru	2018
Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. Addiction biology, 2018, Volume: 23, Issue:6 Topics: Analysis of Variance; Animals; Basal Ganglia; Benzoxazines; Calcium Channel Blockers; Cannabinoids;	2018
Special Issue on Disease: New Advances in Psychiatry. Neuron, 2019, 04-03, Volume: 102, Issue:1 Topics: Animals; Brain; Cerebellum; Depression, Postpartum; Depressive Disorder; Female; gamma-Aminobutyric	2019
[Pregabalin should be moved to the prescription group B]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Mar-19, Volume: 133, Issue:6 Topics: Analgesics; Anticonvulsants; Drug and Narcotic Control; gamma-Aminobutyric Acid; Humans; Pregabalin;	2013
Pregabalin abuse among opiate addicted patients. European journal of clinical pharmacology, 2013, Volume: 69, Issue:12 Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Opiate Substitution T	2013
Acute dystonic reaction caused by gabapentin. The Journal of emergency medicine, 2014, Volume: 46, Issue:3 Topics: Acute Disease; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Dystonia; Gabapentin	2014
Factors associated with pregabalin dispensing at higher than the approved maximum dose. European journal of clinical pharmacology, 2014, Volume: 70, Issue:2 Topics: Adolescent; Adult; Aged; Analgesics; Child; Drug Prescriptions; Female; gamma-Aminobutyric Acid; Hum	2014
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. European addiction research, 2014, Volume: 20, Issue:3 Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti	2014
Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Human psychopharmacology, 2014, Volume: 29, Issue:3 Topics: Benzodiazepines; Central Nervous System Agents; Cognition; Cognition Disorders; Female; Follow-Up St	2014
Gabapentin: can it be misused? Journal of psychosocial nursing and mental health services, 2014, Volume: 52, Issue:1 Topics: Amines; Controlled Substances; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric A	2014
Phenibut, the appearance of another potentially dangerous product in the United States. The American journal of medicine, 2014, Volume: 127, Issue:8 Topics: Adult; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Substance-Related Disorders;	2014
Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic science international, 2014, Volume: 241 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Chromatography, Liquid; Cyclohe	2014
Ketamine alters cortical integration of GABAergic interneurons and induces long-term sex-dependent impairments in transgenic Gad67-GFP mice. Cell death & disease, 2014, Jul-03, Volume: 5 Topics: Animals; Apoptosis; Calcium; Cell Differentiation; Cerebral Cortex; Female; gamma-Aminobutyric Acid;	2014
Ratio of antibodies to neurotransmitters in the serum of students, occasional drug users. Bulletin of experimental biology and medicine, 2014, Volume: 157, Issue:3 Topics: Adolescent; Adult; Autoantibodies; Dopamine; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans;	2014
Injection of crushed tablets--a prospective observational study. Clinical toxicology (Philadelphia, Pa.), 2014, Volume: 52, Issue:9 Topics: Adolescent; Adult; Azabicyclo Compounds; Benzodiazepines; Buprenorphine; C-Reactive Protein; Female;	2014
Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors. Neuropharmacology, 2015, Volume: 97 Topics: Carisoprodol; Dose-Response Relationship, Drug; GABA Agents; gamma-Aminobutyric Acid; HEK293 Cells;	2015
Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. The American journal of psychiatry, 2015, Volume: 172, Issue:5 Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;	2015
Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug and alcohol review, 2016, Volume: 35, Issue:5 Topics: Adult; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Illicit Drugs; Male; Middle Aged; Pre	2016
GABA and Endocannabinoids Mediate Depotentiation of Schaffer Collateral Synapses Induced by Stimulation of Temperoammonic Inputs. PloS one, 2016, Volume: 11, Issue:2 Topics: Animals; Brain; CA1 Region, Hippocampal; Calcium Channels, L-Type; Cognition Disorders; Endocannabin	2016
Abuse of Gabapentin is Associated with Opioid Addiction. The Psychiatric quarterly, 2016, Volume: 87, Issue:4 Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar	2016
A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. CNS drugs, 2016, Volume: 30, Issue:7 Topics: Adult; Amines; Analgesics, Opioid; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Fact	2016
Challenges of fragmented care in long-term management of pelvic pain. The Journal of family practice, 2007, Volume: 56, Issue:3 Suppl Di Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr	2007
[Gabapentin abuse]. Medicina clinica, 2010, Feb-06, Volume: 134, Issue:3 Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric	2010
Gabapentin-induced delirium and dependence. Journal of psychiatric practice, 2009, Volume: 15, Issue:4 Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am	2009
Genetic, personality, and environmental predictors of drug use in adolescents. Journal of substance abuse treatment, 2010, Volume: 38, Issue:2 Topics: Adolescent; Adolescent Behavior; Depression; Dopamine; Family; Female; gamma-Aminobutyric Acid; Gene	2010
Pregabalin treatment of anxiety in patients with substance use disorders. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5 Topics: Anti-Anxiety Agents; Anxiety; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorde	2010
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behavioural pharmacology, 2010, Volume: 21, Issue:4 Topics: Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Cocaine; Dose-Response Relat	2010
A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. European journal of clinical pharmacology, 2010, Volume: 66, Issue:9 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Algorithms; Analgesics; Anticonvulsants;	2010
Pregabalin abuse, dependence, and withdrawal: a case report. The American journal of psychiatry, 2010, Volume: 167, Issue:7 Topics: Alcoholism; Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pregaba	2010
[Abuse of pregabalin]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Sep-09, Volume: 130, Issue:17 Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorder	2010
Earlier discovery of pregabalin's dependence potential might have been possible. European journal of clinical pharmacology, 2011, Volume: 67, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Analgesics; Databases, Factual; gamma-Aminobutyric Acid; Hu	2011
[Yes, pregabalin can be abused!]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Nov-04, Volume: 130, Issue:21 Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorder	2010
Potential for pregabalin abuse or diversion after past drug-seeking behavior. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:10 Topics: Adult; Analgesics; Analgesics, Opioid; Behavior, Addictive; Female; gamma-Aminobutyric Acid; Humans;	2010
Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of α₂/δ-1 subunits of the voltage-gated calcium channels. Neuroscience, 2011, Mar-10, Volume: 176 Topics: Amines; Animals; Blotting, Western; Brain; Calcium Channels; Central Nervous System Stimulants; Cond	2011
Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychotherapy and psychosomatics, 2011, Volume: 80, Issue:2 Topics: Amines; Anticonvulsants; Clonazepam; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Resp	2011
[The prescription registry and abuse of pregabalin]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Feb-04, Volume: 131, Issue:3 Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Norway; Pregabalin;	2011
[To misunderstand about pregabalin abuse]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Apr-08, Volume: 131, Issue:7 Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Norway; Pregabalin;	2011
[Clarification about pregabalin and the Norwegian Prescription Database]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, May-06, Volume: 131, Issue:8 Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Pregabalin; Registri	2011
Pregabalin in the treatment of refractory bipolar disorders. CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:3 Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pregabalin; Substance-Related	2012
[Lyrical tragedy]. Ugeskrift for laeger, 2012, Feb-27, Volume: 174, Issue:9 Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Neuralgia; Pregabalin; Risk Factors; S	2012
Pregabalin in clinical psychiatry and addiction: pros and cons. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9 Topics: Alcoholism; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Calcium Channels; gamma-Aminobutyri	2012
Gabapentin and pregabalin: abuse and addiction. Prescrire international, 2012, Volume: 21, Issue:128 Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Substa	2012
Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addiction. PloS one, 2012, Volume: 7, Issue:7 Topics: Acetates; Animals; Behavior, Animal; Brain; gamma-Aminobutyric Acid; Glucose; Glutamic Acid; Male; M	2012
Pregabalin abuse and dependence in Germany: results from a database query. European journal of clinical pharmacology, 2013, Volume: 69, Issue:6 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Analgesics; Anti-Anxiety Agents; A	2013
[Potentially addictive drugs on reimbursable prescription for chronic severe pain]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Jan-22, Volume: 133, Issue:2 Topics: Analgesics, Opioid; Chronic Pain; Drug Prescriptions; Drug Utilization; gamma-Aminobutyric Acid; Hum	2013
Phenibut dependence. BMJ case reports, 2013, Feb-06, Volume: 2013 Topics: Adult; Baclofen; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives;	2013
GABA systems, benzodiazepines, and substance dependence. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 3 Topics: Alcohol Drinking; Alcohol-Related Disorders; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Hypno	2003
Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2003, Volume: 4, Issue:2 Topics: Adult; Female; Fluoxetine; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Pyridines; Selectiv	2003
Gabapentin for the treatment of ethanol withdrawal. Substance abuse, 2003, Volume: 24, Issue:2 Topics: Acetates; Adult; Alcohol Withdrawal Seizures; Amines; Anticonvulsants; Benzodiazepines; Central Nerv	2003
Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice. Journal of neuroscience research, 2003, Aug-15, Volume: 73, Issue:4 Topics: Analgesics, Opioid; Analysis of Variance; Animals; Brain; Carrier Proteins; Dose-Response Relationsh	2003
The 16th Annual Meeting of the Winter Conference on Neural Plasticity. St. Lucia, West Indies. February 21-28, 2004. CNS drug reviews, 2004,Fall, Volume: 10, Issue:3 Topics: Aging; Animals; Brain; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Gene Expression;	2004
Increased GABA release in the central amygdala of ethanol-dependent rats. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004, Nov-10, Volume: 24, Issue:45 Topics: Alcoholism; Amygdala; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Elect	2004
Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proceedings of the National Academy of Sciences of the United States of America, 2005, Dec-27, Volume: 102, Issue:52 Topics: Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Modulators; Cell	2005
Abuse, dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry, 2007, Volume: 40, Issue:1 Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A	2007
Opioids block long-term potentiation of inhibitory synapses. Nature, 2007, Apr-26, Volume: 446, Issue:7139 Topics: Analgesics, Opioid; Animals; Calcium; Cyclic GMP; Dopamine; gamma-Aminobutyric Acid; In Vitro Techni	2007
Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clinic proceedings, 2007, Volume: 82, Issue:10 Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Flumazenil; Gabapentin; gamma-	2007
Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Molecular psychiatry, 2009, Volume: 14, Issue:2 Topics: Adenosine Triphosphate; Adolescent; Adult; Analysis of Variance; Case-Control Studies; Depressive Di	2009
Pregabalin in the discontinuation of long-term benzodiazepines' use. Human psychopharmacology, 2008, Volume: 23, Issue:4 Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Cognition; Fe	2008
gamma-Aminobutyric acid-ergic analgesia: implications for gamma-aminobutyric acid-ergic therapy for drug addictions. Drug and alcohol dependence, 1984, Volume: 14, Issue:2 Topics: Animals; Baclofen; Brain; Drug Tolerance; Endorphins; GABA Antagonists; gamma-Aminobutyric Acid; Hum	1984
[Benzodiazepine physical dependence. 6 cases (author's transl)]. La Nouvelle presse medicale, 1980, Jun-28, Volume: 9, Issue:28 Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Dreams; Electroencephalography; Female; gamma-Ami	1980
Long term use and abuse of benzodiazepines. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1980, Volume: 13, Issue:5 Topics: Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Female; gamma-Aminobutyric Acid; Humans; Male;	1980
Antagonists of benzodiazepines: functional aspects. Advances in biochemical psychopharmacology, 1983, Volume: 38 Topics: Animals; Anti-Anxiety Agents; Benzodiazepinones; Carbolines; Chlorides; Flumazenil; GABA Antagonists	1983
Neuropharmacology of buspirone. Psychopathology, 1984, Volume: 17 Suppl 3 Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Biomechanical Phenomena; Buspirone;	1984
[Suppression of the opiate withdrawal syndrome with GABA analogs, low-dose psychotropic drugs and acupuncture]. Minerva medica, 1982, Mar-31, Volume: 73, Issue:13 Topics: Acupuncture Therapy; Adult; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Humans; Male;	1982
Glucocorticoid receptor activation potentiates the morphine-induced adaptive increase in dopamine D-1 receptor efficacy in gamma-aminobutyric acid neurons of rat striatum/nucleus accumbens. The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:3 Topics: Adenylyl Cyclases; Animals; Cells, Cultured; Corpus Striatum; Dexamethasone; Enzyme Activation; gamm	1995
[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1995, Volume: 15, Issue:3 Topics: Animals; Binding Sites; Brain; Down-Regulation; Drug Tolerance; gamma-Aminobutyric Acid; In Vitro Te	1995
[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat. II: Strain differences between Lewis and Wistar-Kyoto rats]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1995, Volume: 15, Issue:4 Topics: Animals; Bicuculline; Brain; Chlorine; Ethanol; Female; Flunitrazepam; GABA Antagonists; GABA Modula	1995
Diazepam physical dependence and withdrawal in rats is associated with alteration in GABAA receptor function. Life sciences, 1996, Volume: 59, Issue:19 Topics: Animals; Benzodiazepines; Cerebral Cortex; Chloride Channels; Chlorides; Diazepam; Flumazenil; Fluni	1996
Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology, 1997, Volume: 129, Issue:1 Topics: Animals; Cerebral Cortex; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; gamma-Aminobutyric	1997
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure, 1997, Volume: 6, Issue:2 Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo	1997
Gabapentin abuse in a cocaine user: implications for treatment? Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:5 Topics: Acetates; Adult; Amines; Anticonvulsants; Crack Cocaine; Cyclohexanecarboxylic Acids; Female; Gabape	1997
Drug dependence study on vigabatrin in rhesus monkeys and rats. Arzneimittel-Forschung, 1997, Volume: 47, Issue:10 Topics: Analgesics, Opioid; Animals; Anticonvulsants; Barbital; Conditioning, Operant; Female; gamma-Aminobu	1997
Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends in pharmacological sciences, 1999, Volume: 20, Issue:4 Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Opioid Peptides; Substance-Rel	1999
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders. Annals of the New York Academy of Sciences, 1999, Apr-30, Volume: 868 Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim	1999
GABA GABA A: modulating sensitivity to drugs and alcohol. Molecular psychiatry, 2000, Volume: 5, Issue:1 Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; Substance-Related Disorders	2000
Gabapentin use in benzodiazepine dependence and detoxification. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:3 Topics: Acetates; Alprazolam; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Excitatory Amino Aci	2001
Psychic dependence? A different formulation of the problem with a view to the reorientation of therapy for chronic drug addiction. Acta psychiatrica Scandinavica, 1977, Volume: 56, Issue:5 Topics: Aminobutyrates; Antidepressive Agents, Tricyclic; Depression; gamma-Aminobutyric Acid; Glutamine; Hu	1977
Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal. European journal of pharmacology, 1979, Apr-15, Volume: 55, Issue:2 Topics: Acoustic Stimulation; Animals; Barbital; Barbiturates; Brain; Cyclic AMP; Cyclic GMP; gamma-Aminobut	1979
[Psychological dependence? A possible different formulation of the problem for a therapeutic rearrangement in chronic drug addictions]. Minerva medica, 1977, Jul-07, Volume: 68, Issue:33 Topics: Antidepressive Agents; gamma-Aminobutyric Acid; Glutamine; Humans; Piracetam; Substance-Related Diso	1977
Physiologo-biochemical bases of drug dependence treatment by electro-acupuncture. Addictive behaviors, 1979, Volume: 4, Issue:2 Topics: Acetylcholine; Acupuncture Therapy; Catecholamines; Electric Stimulation; gamma-Aminobutyric Acid; H	1979
[Gynecomastia during benzodiazepine abuse]. Ugeskrift for laeger, 1979, Sep-24, Volume: 141, Issue:39 Topics: Diazepam; gamma-Aminobutyric Acid; Gynecomastia; Humans; Male; Middle Aged; Pituitary Gland, Anterio	1979
Changes of taurine content in the brain tissue of barbiturate-dependent rats. Biochemical pharmacology, 1978, Volume: 27, Issue:15 Topics: Animals; Aspartic Acid; Barbiturates; Brain Chemistry; gamma-Aminobutyric Acid; Glutamates; Humans;	1978
Effects of the irreversible inhibition of GABA transaminase upon some morphine effects. Neuropharmacology, 1979, Volume: 18, Issue:3 Topics: 4-Aminobutyrate Transaminase; Analgesia; Animals; Drug Tolerance; Female; gamma-Aminobutyric Acid; H	1979
Pharmacological manipulation of gamma-aminobutyric acid (GABA) in morphine analgesia, tolerance and physical dependence. Life sciences, 1976, May-15, Volume: 18, Issue:10 Topics: Alanine; Aminobutyrates; Aminooxyacetic Acid; Analgesia; Animals; Bicuculline; Biological Transport;	1976
Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats. European journal of pharmacology, 1992, Mar-31, Volume: 213, Issue:3 Topics: Amino Acids; Aminocaproates; Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Drug Admini	1992
The effect of ethanol on 35S-TBPS binding to mouse brain membranes in the presence of chloride. Pharmacology & toxicology, 1989, Volume: 65, Issue:5 Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo	1989
From the Alcohol, Drug Abuse, and Mental Health Administration. JAMA, 1989, May-12, Volume: 261, Issue:18 Topics: Diabetes Mellitus, Type 2; Ethanol; Female; Fetal Growth Retardation; gamma-Aminobutyric Acid; Human	1989
Evidence for GABA tolerance in barbiturate-dependent and withdrawn mice. Neuropharmacology, 1985, Volume: 24, Issue:5 Topics: Animals; Barbital; Barbiturates; Drug Tolerance; Female; gamma-Aminobutyric Acid; Humans; Imidazoles	1985
[Short- and long-acting benzodiazepines]. Nederlands tijdschrift voor geneeskunde, 1988, Oct-15, Volume: 132, Issue:42 Topics: Absorption; Benzodiazepines; Drug Tolerance; gamma-Aminobutyric Acid; Humans; Substance-Related Diso	1988

gamma-aminobutyric acid and Chemical Dependence